Amarin Co. plc (NASDAQ:AMRN) insider Steven B. Ketchum sold 128,257 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $4.25, for a total transaction of $545,092.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Amarin Co. plc (NASDAQ AMRN) traded up $0.16 during trading on Friday, reaching $4.35. 1,330,229 shares of the company traded hands, compared to its average volume of 1,414,720. The stock has a market capitalization of $1,180.00, a PE ratio of -16.11 and a beta of 0.62. The company has a current ratio of 1.63, a quick ratio of 1.32 and a debt-to-equity ratio of -1.48. Amarin Co. plc has a 1-year low of $2.81 and a 1-year high of $4.47.
Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million during the quarter, compared to the consensus estimate of $45.85 million. The business’s revenue was up 45.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.08) EPS. equities analysts predict that Amarin Co. plc will post -0.22 EPS for the current fiscal year.
Several research analysts recently weighed in on AMRN shares. Cantor Fitzgerald restated a “buy” rating and set a $10.00 price target on shares of Amarin in a report on Thursday, September 14th. Zacks Investment Research upgraded shares of Amarin from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Tuesday, October 3rd. Jefferies Group restated a “buy” rating on shares of Amarin in a report on Wednesday, October 11th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Amarin in a report on Thursday, November 2nd. Finally, ValuEngine upgraded shares of Amarin from a “sell” rating to a “hold” rating in a report on Saturday, November 4th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $7.75.
A number of hedge funds have recently made changes to their positions in AMRN. Alkeon Capital Management LLC bought a new stake in Amarin in the third quarter worth about $7,875,000. University of Notre Dame DU Lac bought a new stake in Amarin in the third quarter worth about $2,814,000. JPMorgan Chase & Co. raised its position in Amarin by 681.5% in the second quarter. JPMorgan Chase & Co. now owns 278,134 shares of the biopharmaceutical company’s stock worth $1,121,000 after acquiring an additional 242,544 shares during the period. GSA Capital Partners LLP raised its position in Amarin by 135.4% in the second quarter. GSA Capital Partners LLP now owns 342,800 shares of the biopharmaceutical company’s stock worth $1,381,000 after acquiring an additional 197,200 shares during the period. Finally, Intrinsic Edge Capital Management LLC bought a new stake in Amarin in the second quarter worth about $725,000. 40.12% of the stock is currently owned by institutional investors and hedge funds.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.